Why Prelude Therapeutics Incorporated’s (PRLD) Stock Is Down 6.07%
As of Friday, August 28, Prelude Therapeutics Incorporated’s PRLD share price has dipped by 6.07%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Prelude Therapeutics Incorporated (PRLD)
Prelude Therapeutics Incorporated PRLD
$5.43
-0.06
-1.09%
September 2, 2026 4:00:00 PM
EST
Volume: 355,072
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Commentary & Analysis
Why Prelude Therapeutics Incorporated’s (PRLD) Stock Is Down 6.33%
As of Monday, August 24, Prelude Therapeutics Incorporated’s PRLD share price has dipped by 6.33%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Prelude Therapeutics Incorporated’s (PRLD) Stock Is Down 11.08%
As of Friday, August 21, Prelude Therapeutics Incorporated’s PRLD share price has dipped by 11.08%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Is Prelude Therapeutics Incorporated (PRLD) Overvalued?
We dive into why Prelude Therapeutics Incorporated (PRLD) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Michael Rose
Why Prelude Therapeutics Incorporated’s (PRLD) Stock Is Up 5.59%
As of Monday, August 17, Prelude Therapeutics Incorporated’s PRLD share price has surged by 5.59%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | PRLD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $559.3 | $288.9 | 38% |
|
| Shares Out (Mil) | 98.4 | 54.0 | 62% |
|
| Institutional Ownership | 82.2% | 93.1% | 50% |
|
| Float (Mil) | 22.1 | 41.4 | 30% |
|
| Beta | 0.94 | 0.94 | 56% |
|
| Avg Daily Volume (000s) | 708 | 480 | 65% |
|
| Price Change (52-week) |
380.5% | 59.9% | 99% |
|
| Growth | PRLD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (11.8%) | (10.1%) | 27% |
|
| EPS (5yr) | 22.3% | 15.9% | 72 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (55.1%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.140) | ($0.540) | ($0.750) | |
| Month Ago EPS | ($0.170) | ($0.655) | ($0.860) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.240) | ($0.950) | ($0.940) | |
| Year/Year Chg | (0.7%) | (58.2%) | (146.4%) | |
| Financials | PRLD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $22 | $37 | 14% |
|
| Net Income (TTM) (Mil) | ($61) | ($43) | 15% |
|
| EPS (TTM) | ($0.718) | ($1.500) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($33) | ($31) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $2 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $15 | $4 | 31% |
|
| Enterprise Value (Q1) (Mil) | $418 | $190 | 32% |
|
| Valuation | PRLD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.18 | 2.84 | 74% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PRLD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | (269.7%) | (74.2%) | 3% |
|
| ROA | (39.8%) | (47.7%) | 14% |
|
| ROE | (57.7%) | (55.0%) | 14% |
|
| Liabilities to Assets | 29.4% | 29.6% | 21% |
|
| F-Score | 3 | 3 | 18% |
|
Prelude Therapeutics Incorporated did not pass any screens on 9/2/2026.
